Review of cancer treatment with immune checkpoint inhibitors: Current concepts, expectations, limitations and pitfalls

Summary Immunotherapy by checkpoint inhibition is about to profoundly change cancer therapy. The number of indications are growing at an unprecedented speed. Clinical studies have demonstrated efficacy in a variety of solid tumors and in hematologic malignancies, although some clinical trials have p...

Full description

Saved in:
Bibliographic Details
Published in:Wiener Klinische Wochenschrift 2018-02, Vol.130 (3-4), p.85-91
Main Authors: Thallinger, Christiane, Füreder, Thorsten, Preusser, Matthias, Heller, Gerwin, Müllauer, Leonhard, Höller, Christoph, Prosch, Helmut, Frank, Natalija, Swierzewski, Rafal, Berger, Walter, Jäger, Ulrich, Zielinski, Christoph
Format: Article
Language:English
Subjects:
Drug-Related Side Effects and Adverse Reactions
Endocrinology
Gastroenterology
Humans
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Motivation
Neoplasms - therapy
Pneumology/Respiratory System
Review
Review Article
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Immunotherapy by checkpoint inhibition is about to profoundly change cancer therapy. The number of indications are growing at an unprecedented speed. Clinical studies have demonstrated efficacy in a variety of solid tumors and in hematologic malignancies, although some clinical trials have produced negative results. Thus, it is fair to assume that there are obvious limitations and pitfalls in immunotherapy. Future concepts for combination treatment of immune checkpoint inhibitors have to be developed, but there is also urgent need for better and standardized biomarkers to identify those cancer patients who will benefit from treatment by checkpoint inhibition. The current overview summarizes current knowledge on immune checkpoint inhibitor treatment in malignancies, its outlook and limitations, diagnostic means and, finally, side effect management.
ISSN:0043-5325
1613-7671
DOI:10.1007/s00508-017-1285-9